A Phase 2 interventional study of Cefiderocol and Imipenem/cilastatin in Urinary Tract Infections, sponsored by Shionogi. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-12.
Sponsored by Shionogi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study was to determine the efficacy and safety of intravenous cefiderocol (S-649266) in hospitalized adults with complicated urinary tract infections caused by Gram-negative pathogens.
806 studies on the registry are indexed under Urinary Tract Infections; 134 are open to participants now.
This study's enrollment of 452 is above the median of 133 across 562 interventional studies indexed under Urinary Tract Infections.
Browse Urinary Tract Infections studies →Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
cUTI diagnosed with a history of ≥ 1 of the following:
At least 2 of the following signs or symptoms:
All subjects had to have urinalysis evidence of pyuria demonstrated by 1 of the following:
≥ 10 white blood cells (WBCs) per μL in unspun urine, or ≥ 10 WBCs per high power field in spun urine
Exclusion Criteria:
Participants received 2 g cefiderocol by intravenous injection once every 8 hours for 7 to 14 days.
Drug: Cefiderocol
Participants received 1 g each of imipenem/cilastatin by intravenous injection once every 8 hours for 7 to 14 days.
Drug: Imipenem/cilastatin
2000 mg intravenously every 8 hours for 7 to 14 days; dose adjustments for participants with reduced renal function (estimated CrCl ≤ 70 mL/minute) and/or body weight (\< 70 kg) included every 6-hour dosing intervals and/or reduced doses.
Also known as: FETROJA®, S-649266
Drug pages: Imipenem · Cilastatin
1000 mg of each intravenously every 8 hours for 7 to 14 days; dose adjustments for participants with reduced renal function (estimated CrCl ≤ 70 mL/minute) and/or body weight (\< 70 kg) included every 6-hour dosing intervals and/or reduced doses.
Also known as: PRIMAXIN®
Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Test of Cure
The primary efficacy endpoint was the composite outcome of clinical response and microbiological response at the test of cure assessment, defined as 7 days (±2 days) after the end of antibiotic treatment. Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms. Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.
Time frame: Test of cure (TOC; 7 days after end of treatment [EOT], equivalent to Study Day 14 to 21)
Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Early Assessment
A composite outcome of clinical response and microbiological response at the early assessment, defined as Day 4 of antibiotic treatment. Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms. Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.
Time frame: Early assessment (EA; Day 4)
Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at End of Treatment
A composite outcome of clinical response and microbiological response at the end of treatment, defined as the end of the last infusion of antibiotic treatment. Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms. Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.
Time frame: End of treatment (EOT; Day 7 to 14)
Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Follow-up
A composite response of clinical response and microbiological response at the follow-up assessment, defined as 14 days after the end of treatment. Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with sustained response defined as all pre-therapy signs and symptoms of cUTI show no evidence of recurrence after administration of the last dose of study drug. Microbiological outcome was based on quantitative microbiological urine cultures, with sustained eradication defined as a urine culture obtained after documented eradication at the TOC, up to and including the FUP, showed that the bacterial uropathogen(s) identified at baseline at ≥ 10⁵ CFU/mL remained \< 10⁴ CFU/mL.
Time frame: Follow-up (FUP; 14 days after end of treatment, Day 21 to 28)
Percentage of Participants With Microbiological Eradication at Test of Cure
Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as all bacterial uropathogens found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.
Time frame: Test of cure (7 days after end of treatment, Day 14 to 21)
Percentage of Participants With Microbiological Eradication at Early Assessment
Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as all bacterial uropathogens found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.
Time frame: Early assessment, Day 4
Percentage of Participants With Microbiological Eradication at End of Treatment
Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as all bacterial uropathogens found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.
Time frame: End of treatment, Day 7 to 14
Percentage of Participants With Microbiological Eradication at Follow-up
Microbiological outcome was based on quantitative microbiological urine cultures, with sustained eradication defined as a urine culture obtained after documented eradication at the TOC, up to and including the FUP, where the bacterial uropathogen(s) identified at baseline at ≥ 10⁵ CFU/mL remained \< 10⁴ CFU/mL.
Time frame: Follow-up, 14 days after end of treatment, Day 21 to 28
Percentage of Participants With Microbiological Eradication at Test of Cure Per Uropathogen
Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.
Time frame: Test of cure; 7 days after end of treatment, Day 14 to 21
Percentage of Participants With Microbiological Eradication at Early Assessment Per Uropathogen
Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.
Time frame: Early assessment, Day 4
Percentage of Participants With Microbiological Eradication at End of Treatment Per Uropathogen
Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.
Time frame: End of treatment, Day 7 to 14
Percentage of Participants With Microbiological Eradication at Follow-up Per Uropathogen
Microbiological outcome was based on quantitative microbiological urine cultures, with sustained eradication defined as a urine culture obtained after documented eradication at the TOC, up to and including the FUP, where the bacterial uropathogen identified at baseline at ≥ 10⁵ CFU/mL remained \< 10⁴ CFU/mL. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.
Time frame: Follow-up, 14 days after the end of treatment, Day 21 to 28
Percentage of Participants With Clinical Response at Test of Cure
Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms.
Time frame: Test of cure, 7 days after end of treatment, Day 14 to 21
Percentage of Participants With Clinical Response at Early Assessment
Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms.
Time frame: Early assessment, Day 4
Percentage of Participants With Clinical Response at End of Treatment
Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms.
Time frame: End of treatment, Day 7 to 14
Percentage of Participants With Clinical Response at Follow-up
Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with sustained response defined as all pre-therapy signs and symptoms of cUTI showing no evidence of recurrence after administration of the last dose of study drug.
Time frame: Follow-up, 14 days after end of treatment, Day 21 to 28
Percentage of Participants With Clinical Response at Test of Cure Per Uropathogen
Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.
Time frame: Test of cure, 7 days after end of treatment, Day 14 to 21
Percentage of Participants With Clinical Response at Early Assessment Per Uropathogen
Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.
Time frame: Early assessment, Day 4
Percentage of Participants With Clinical Response at End of Treatment Per Uropathogen
Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.
Time frame: End of treatment, Day 7 to 14
Percentage of Participants With Clinical Response at Follow-up Per Uropathogen
Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with sustained response defined as all pre-therapy signs and symptoms of cUTI show no evidence of recurrence after administration of the last dose of study drug. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.
Time frame: Follow-up, 14 days after the end of treatment, Day 21 to 28
Plasma Concentration of Cefiderocol
Time frame: On Day 3 of dosing prior to infusion, end of infusion, and at 1 hour post infusion
Urine Concentration of Cefiderocol
Time frame: Day 3, 2 hours and 6 hours after end of infusion
Number of Participants With Adverse Events
A serious adverse event was defined by regulation as any adverse event (AE) occurring at any dose that resulted in any of the following outcomes: * Death * Life-threatening condition * Hospitalization or prolongation of existing hospitalization * Persistent or significant disability/incapacity * Congenital anomaly/birth defect * Other medically important condition. The relationship of an event to the study drug was determined by the investigator based on whether the AE could be reasonably explained as being caused by the study drug.
Time frame: From first dose of study drug until 28 days after end of treatment; Day 35 to 42
This study was conducted at 67 hospitals in 15 countries. Participants diagnosed with complicated urinary tract infections (cUTIs) with or without pyelonephritis or acute uncomplicated pyelonephritis were enrolled from February 5, 2015 to August 16, 2016.
| Milestone | Cefiderocol | Imipenem/Cilastatin |
|---|---|---|
| Started | 303 | 149 |
| Received study drug | 300 | 148 |
| Completed | 283 | 138 |
| Not completed | 20 | 11 |
| Withdrew: Withdrawal by subject | 3 | 3 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Lost to follow-up | 10 | 4 |
| Withdrew: Adverse event | 2 | 3 |
| Withdrew: Other, miscellaneous | 3 | 1 |
The primary efficacy endpoint was the composite outcome of clinical response and microbiological response at the test of cure assessment, defined as 7 days (±2 days) after the end of antibiotic treatment. Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms. Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.
| percentage of participants | Cefiderocol | Imipenem/Cilastatin |
|---|---|---|
| Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Test of Cure | 72.6 | 54.6 |
A composite outcome of clinical response and microbiological response at the early assessment, defined as Day 4 of antibiotic treatment. Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms. Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.
| percentage of participants | Cefiderocol | Imipenem/Cilastatin |
|---|---|---|
| Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Early Assessment | 88.1 | 87.4 |
A composite outcome of clinical response and microbiological response at the end of treatment, defined as the end of the last infusion of antibiotic treatment. Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms. Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.
| percentage of participants | Cefiderocol | Imipenem/Cilastatin |
|---|---|---|
| Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at End of Treatment | 96.4 | 95.8 |
A composite response of clinical response and microbiological response at the follow-up assessment, defined as 14 days after the end of treatment. Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with sustained response defined as all pre-therapy signs and symptoms of cUTI show no evidence of recurrence after administration of the last dose of study drug. Microbiological outcome was based on quantitative microbiological urine cultures, with sustained eradication defined as a urine culture obtained after documented eradication at the TOC, up to and including the FUP, showed that the bacterial uropathogen(s) identified at baseline at ≥ 10⁵ CFU/mL remained \< 10⁴ CFU/mL.
| percentage of participants | Cefiderocol | Imipenem/Cilastatin |
|---|---|---|
| Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Follow-up | 54.4 | 39.5 |
Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as all bacterial uropathogens found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.
| percentage of participants | Cefiderocol | Imipenem/Cilastatin |
|---|---|---|
| Percentage of Participants With Microbiological Eradication at Test of Cure | 73.0 | 56.3 |
Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as all bacterial uropathogens found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.
| percentage of participants | Cefiderocol | Imipenem/Cilastatin |
|---|---|---|
| Percentage of Participants With Microbiological Eradication at Early Assessment | 92.1 | 90.8 |
Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as all bacterial uropathogens found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.
| percentage of participants | Cefiderocol | Imipenem/Cilastatin |
|---|---|---|
| Percentage of Participants With Microbiological Eradication at End of Treatment | 96.8 | 95.8 |
Microbiological outcome was based on quantitative microbiological urine cultures, with sustained eradication defined as a urine culture obtained after documented eradication at the TOC, up to and including the FUP, where the bacterial uropathogen(s) identified at baseline at ≥ 10⁵ CFU/mL remained \< 10⁴ CFU/mL.
| percentage of participants | Cefiderocol | Imipenem/Cilastatin |
|---|---|---|
| Percentage of Participants With Microbiological Eradication at Follow-up | 57.1 | 43.7 |
Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.
| percentage of participants | Cefiderocol | Imipenem/Cilastatin |
|---|---|---|
| Escherichia coli | 75.0 | 58.2 |
| Klebsiella pneumoniae | 75.0 | 52.0 |
| Pseudomonas aeruginosa | 44.4 | 60.0 |
| Proteus mirabilis | 76.5 | 50.0 |
Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.
| percentage of participants | Cefiderocol | Imipenem/Cilastatin |
|---|---|---|
| Escherichia coli | 92.8 | 94.9 |
| Klebsiella pneumoniae | 89.6 | 88.0 |
| Pseudomonas aeruginosa | 94.4 | 80.0 |
| Proteus mirabilis | 88.2 | 100.0 |
Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.
| percentage of participants | Cefiderocol | Imipenem/Cilastatin |
|---|---|---|
| Escherichia coli | 98.7 | 97.5 |
| Klebsiella pneumoniae | 97.9 | 92.0 |
| Pseudomonas aeruginosa | 88.9 | 100.0 |
| Proteus mirabilis | 94.1 | 100.0 |
Microbiological outcome was based on quantitative microbiological urine cultures, with sustained eradication defined as a urine culture obtained after documented eradication at the TOC, up to and including the FUP, where the bacterial uropathogen identified at baseline at ≥ 10⁵ CFU/mL remained \< 10⁴ CFU/mL. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.
| percentage of participants | Cefiderocol | Imipenem/Cilastatin |
|---|---|---|
| Escherichia coli | 59.9 | 41.8 |
| Klebsiella pneumoniae | 58.3 | 52.0 |
| Pseudomonas aeruginosa | 27.8 | 20.0 |
| Proteus mirabilis | 64.7 | 0 |
Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms.
| percentage of participants | Cefiderocol | Imipenem/Cilastatin |
|---|---|---|
| Percentage of Participants With Clinical Response at Test of Cure | 89.7 | 87.4 |
Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms.
| percentage of participants | Cefiderocol | Imipenem/Cilastatin |
|---|---|---|
| Percentage of Participants With Clinical Response at Early Assessment | 90.5 | 90.8 |
Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms.
| percentage of participants | Cefiderocol | Imipenem/Cilastatin |
|---|---|---|
| Percentage of Participants With Clinical Response at End of Treatment | 98.0 | 99.2 |
Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with sustained response defined as all pre-therapy signs and symptoms of cUTI showing no evidence of recurrence after administration of the last dose of study drug.
| percentage of participants | Cefiderocol | Imipenem/Cilastatin |
|---|---|---|
| Percentage of Participants With Clinical Response at Follow-up | 81.3 | 72.3 |
Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.
| percentage of participants | Cefiderocol | Imipenem/Cilastatin |
|---|---|---|
| Escherichia coli | 89.7 | 88.3 |
| Klebsiella pneumoniae | 89.1 | 84.0 |
| Pseudomonas aeruginosa | 73.3 | 75.0 |
| Proteus mirabilis | 100.0 | 100.0 |
Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.
| percentage of participants | Cefiderocol | Imipenem/Cilastatin |
|---|---|---|
| Escherichia coli | 91.8 | 96.1 |
| Klebsiella pneumoniae | 82.6 | 88.0 |
| Pseudomonas aeruginosa | 93.3 | 75.0 |
| Proteus mirabilis | 84.6 | 100.0 |
Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.
| percentage of participants | Cefiderocol | Imipenem/Cilastatin |
|---|---|---|
| Escherichia coli | 97.9 | 98.7 |
| Klebsiella pneumoniae | 100.0 | 100.0 |
| Pseudomonas aeruginosa | 93.3 | 100.0 |
| Proteus mirabilis | 100.0 | 100.0 |
Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with sustained response defined as all pre-therapy signs and symptoms of cUTI show no evidence of recurrence after administration of the last dose of study drug. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.
| percentage of participants | Cefiderocol | Imipenem/Cilastatin |
|---|---|---|
| Escherichia coli | 82.9 | 72.7 |
| Klebsiella pneumoniae | 82.6 | 68.0 |
| Pseudomonas aeruginosa | 53.3 | 75.0 |
| Proteus mirabilis | 84.6 | 100.0 |
| µg/mL | Cefiderocol |
|---|---|
| Pre-infusion | 18.0 ± 18.3 |
| End of infusion | 141 ± 220 |
| 1 hour after end of infusion | 70.2 ± 30.4 |
| µg/mL | Cefiderocol |
|---|---|
| 2 hours after end of infusion | 2710 ± 1520 |
| 6 hours after end of infusion | 1520 ± 1370 |
A serious adverse event was defined by regulation as any adverse event (AE) occurring at any dose that resulted in any of the following outcomes: * Death * Life-threatening condition * Hospitalization or prolongation of existing hospitalization * Persistent or significant disability/incapacity * Congenital anomaly/birth defect * Other medically important condition. The relationship of an event to the study drug was determined by the investigator based on whether the AE could be reasonably explained as being caused by the study drug.
| Participants | Cefiderocol | Imipenem/Cilastatin |
|---|---|---|
| All adverse events | 122 | 76 |
| Drug-related adverse events | 27 | 17 |
| Deaths | 1 | 0 |
| Serious adverse events | 14 | 12 |
| Drug-related serious adverse events | 1 | 1 |
| Discontinuation of study drug due to AE | 5 | 3 |
| Discontinuation due to drug-related AE | 3 | 0 |
Collected over From first dose of study drug until 28 days after end of treatment; Day 35 to 42. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| S-649266 | 1/300 (0.3%) | 14/300 (4.7%) | 60/300 (20%) |
| Imipenem/Cilastatin | 0/148 (0%) | 12/148 (8.1%) | 48/148 (32.4%) |
| Event | S-649266 | Imipenem/Cilastatin |
|---|---|---|
| Clostridium difficile colitisInfections and infestations | 1/300 | 2/148 |
| Cardiac failureCardiac disorders | 1/300 | 1/148 |
| Congenital ureteric anomalyCongenital, familial and genetic disorders | 0/300 | 1/148 |
| DiarrhoeaGastrointestinal disorders | 1/300 | 1/148 |
| Lower gastrointestinal haemorrhageGastrointestinal disorders | 0/300 | 1/148 |
| AbscessInfections and infestations | 0/300 | 1/148 |
| Device related infectionInfections and infestations | 0/300 | 1/148 |
| Prostatic abscessInfections and infestations | 0/300 | 1/148 |
| PyelonephritisInfections and infestations | 0/300 | 1/148 |
| Alcohol poisoningInjury, poisoning and procedural complications | 0/300 | 1/148 |
| Event | S-649266 | Imipenem/Cilastatin |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 12/300 | 8/148 |
| HeadacheNervous system disorders | 7/300 | 8/148 |
| HypertensionVascular disorders | 13/300 | 8/148 |
| ConstipationGastrointestinal disorders | 10/300 | 6/148 |
| NauseaGastrointestinal disorders | 7/300 | 6/148 |
| Abdominal pain upperGastrointestinal disorders | 2/300 | 5/148 |
| Infusion site painGeneral disorders | 9/300 | 5/148 |
| Renal cystRenal and urinary disorders | 4/300 | 5/148 |
| HypokalaemiaMetabolism and nutrition disorders | 5/300 | 4/148 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/300 | 1/148 |
Modified intent-to-treat population includes all randomly assigned participants who received at least one dose of study drug and had qualifying Gram-negative uropathogen (≥1 × 10⁵ colony forming unit (CFU)/mL)
| Age, Continuous(years) | Cefiderocol | Imipenem/Cilastatin | Total |
|---|---|---|---|
| Mean | 62.3 ± 16.10 | 61.3 ± 18.48 | 62.0 ± 16.88 |
| Age, Customized(Participants) | Cefiderocol | Imipenem/Cilastatin | Total |
|---|---|---|---|
| < 65 years | 113 | 54 | 167 |
| >= 65 years | 139 | 65 | 204 |
| Sex: Female, Male(Participants) | Cefiderocol | Imipenem/Cilastatin | Total |
|---|---|---|---|
| Female | 133 | 71 | 204 |
| Male | 119 | 48 | 167 |
| Ethnicity (NIH/OMB)(Participants) | Cefiderocol | Imipenem/Cilastatin | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 1 | 6 |
| Not Hispanic or Latino | 247 | 118 | 365 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Cefiderocol | Imipenem/Cilastatin | Total |
|---|---|---|---|
| White | 241 | 115 | 356 |
| Black or African American | 1 | 0 | 1 |
| Asian | 9 | 4 | 13 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Creatinine Clearance Renal Grading Group(Participants) | Cefiderocol | Imipenem/Cilastatin | Total |
|---|---|---|---|
| > 80 mL/min (Normal) | 124 | 51 | 175 |
| > 50 - 80 mL/min (Mild) | 78 | 41 | 119 |
| 30 - 50 mL/min (Moderate) | 41 | 23 | 64 |
| < 30 mL/min (Severe) | 7 | 4 | 11 |
| Clinical Diagnosis at Baseline(Participants) | Cefiderocol | Imipenem/Cilastatin | Total |
|---|---|---|---|
| cUTI with pyelonephritis | 65 | 29 | 94 |
| cUTI without pyelonephritis | 122 | 55 | 177 |
| Acute Uncomplicated Pyelonephritis | 65 | 35 | 100 |
| Number of Gram-negative Uropathogens > 10⁵ CFU/mL Isolated at Baseline(Participants) | Cefiderocol | Imipenem/Cilastatin | Total |
|---|---|---|---|
| 1 uropathogen | 241 | 115 | 356 |
| 2 uropathogens | 11 | 4 | 15 |
No study locations are listed for this record.
Ran from Feb 2015 to primary completion in Jul 2016, 17 months.
Results were first posted in Dec 2019, 3 years 4 months after primary completion. A results delay was requested in Jul 2017.
Of 30 phase 2 interventional studies under Urinary Tract Infections, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 38. This study's 17 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cefiderocol